vom Dorp F - Search Results

1

Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer.

Szarvas T, Jäger T, Tötsch M, vom Dorp F, Kempkensteffen C, Kovalszky I, Romics I, Ergün S, Rübben H. Szarvas T, et al. Among authors: vom dorp f. Clin Cancer Res. 2008 Dec 15;14(24):8253-62. doi: 10.1158/1078-0432.CCR-08-0677. Clin Cancer Res. 2008. PMID: 19088043

2

Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer.

Szarvas T, Jäger T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, Rübben H, Ergün S, vom Dorp F. Szarvas T, et al. Among authors: vom dorp f. Pathol Oncol Res. 2011 Jun;17(2):325-32. doi: 10.1007/s12253-010-9320-4. Epub 2011 Jan 21. Pathol Oncol Res. 2011. PMID: 21253919 Free article.

3

Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Szarvas T, vom Dorp F, Ergün S, Rübben H. Szarvas T, et al. Among authors: vom dorp f. Nat Rev Urol. 2011 May;8(5):241-54. doi: 10.1038/nrurol.2011.44. Epub 2011 Apr 12. Nat Rev Urol. 2011. PMID: 21487384 Review.

4

Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer.

Szarvas T, László V, Vom Dorp F, Reis H, Szendröi A, Romics I, Tilki D, Rübben H, Ergün S. Szarvas T, et al. Among authors: vom dorp f. Int J Cancer. 2012 Jun 15;130(12):2922-9. doi: 10.1002/ijc.26343. Epub 2011 Sep 22. Int J Cancer. 2012. PMID: 21815140

5

High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer.

Szarvas T, vom Dorp F, Niedworok C, Melchior-Becker A, Fischer JW, Singer BB, Reis H, Bánkfalvi Á, Schmid KW, Romics I, Ergün S, Rübben H. Szarvas T, et al. Among authors: vom dorp f. BJU Int. 2012 Sep;110(6 Pt B):E308-17. doi: 10.1111/j.1464-410X.2012.11149.x. Epub 2012 Apr 13. BJU Int. 2012. PMID: 22500655

6

Circulating angiostatin, bFGF, and Tie2/TEK levels and their prognostic impact in bladder cancer.

Szarvas T, Jäger T, Laszlo V, Kramer G, Klingler HC, vom Dorp F, Romics I, Ergün S, Rübben H. Szarvas T, et al. Among authors: vom dorp f. Urology. 2012 Sep;80(3):737.e13-8. doi: 10.1016/j.urology.2012.03.023. Epub 2012 May 17. Urology. 2012. PMID: 22607948

7

Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer.

Szarvas T, Becker M, vom Dorp F, Gethmann C, Tötsch M, Bánkfalvi A, Schmid KW, Romics I, Rübben H, Ergün S. Szarvas T, et al. Among authors: vom dorp f. Cancer Sci. 2010 May;101(5):1300-8. doi: 10.1111/j.1349-7006.2010.01506.x. Epub 2010 Jan 20. Cancer Sci. 2010. PMID: 20180812 Free PMC article.

8

Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer.

Becker M, Szarvas T, Wittschier M, vom Dorp F, Tötsch M, Schmid KW, Rübben H, Ergün S. Becker M, et al. Among authors: vom dorp f. Cancer. 2010 Oct 1;116(19):4502-12. doi: 10.1002/cncr.25326. Cancer. 2010. PMID: 20564745 Free article.

9

Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer.

Szarvas T, Singer BB, Becker M, Vom Dorp F, Jäger T, Szendroi A, Riesz P, Romics I, Rübben H, Ergün S. Szarvas T, et al. Among authors: vom dorp f. BJU Int. 2011 Apr;107(7):1069-73. doi: 10.1111/j.1464-410X.2010.09625.x. Epub 2010 Sep 3. BJU Int. 2011. PMID: 20825402

10

[Value of systemic chemotherapy in bladder cancer].

Goebell PJ, vom Dorp F, Rübben H. Goebell PJ, et al. Among authors: vom dorp f. Urologe A. 2006 May;45(5):586, 588-90, 592-3. doi: 10.1007/s00120-006-1058-y. Urologe A. 2006. PMID: 16710678 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters